FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q102063374> ?p ?o ?g. }

• Q102063374 description "2020 nî lūn-bûn" @default.
• Q102063374 description "2020 ވަނަ އަހަރުގެ ނޮވެމްބަރުމަހުގެ 14ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
• Q102063374 description "2020年の論文" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年学术文章" @default.
• Q102063374 description "2020年學術文章" @default.
• Q102063374 description "2020年學術文章" @default.
• Q102063374 description "2020年學術文章" @default.
• Q102063374 description "2020年學術文章" @default.
• Q102063374 description "2020年學術文章" @default.
• Q102063374 description "2020년 논문" @default.
• Q102063374 description "article científic" @default.
• Q102063374 description "article scientific" @default.
• Q102063374 description "article scientifique" @default.
• Q102063374 description "articol științific" @default.
• Q102063374 description "articolo scientifico" @default.
• Q102063374 description "artigo científico" @default.
• Q102063374 description "artigo científico" @default.
• Q102063374 description "artigo científico" @default.
• Q102063374 description "artikel ilmiah" @default.
• Q102063374 description "artikull shkencor" @default.
• Q102063374 description "artikulong pang-agham" @default.
• Q102063374 description "artykuł naukowy" @default.
• Q102063374 description "artículo científico publicado en 2020" @default.
• Q102063374 description "artículu científicu" @default.
• Q102063374 description "bilimsel makale" @default.
• Q102063374 description "bài báo khoa học" @default.
• Q102063374 description "naučni članak" @default.
• Q102063374 description "scienca artikolo" @default.
• Q102063374 description "scientific article published on 14 November 2020" @default.
• Q102063374 description "scientific article published on 14 November 2020" @default.
• Q102063374 description "scientific article published on 14 November 2020" @default.
• Q102063374 description "teaduslik artikkel" @default.
• Q102063374 description "tieteellinen artikkeli" @default.
• Q102063374 description "tudományos cikk" @default.
• Q102063374 description "vedecký článok" @default.
• Q102063374 description "vetenskaplig artikel" @default.
• Q102063374 description "videnskabelig artikel udgivet 14. november 2020" @default.
• Q102063374 description "vitenskapelig artikkel" @default.
• Q102063374 description "vitskapeleg artikkel" @default.
• Q102063374 description "vědecký článek" @default.
• Q102063374 description "wetenschappelijk artikel" @default.
• Q102063374 description "wissenschaftlicher Artikel" @default.
• Q102063374 description "επιστημονικό άρθρο" @default.
• Q102063374 description "мақолаи илмӣ" @default.
• Q102063374 description "наукова стаття, опублікована в листопаді 2020" @default.
• Q102063374 description "научна статия" @default.
• Q102063374 description "научная статья" @default.
• Q102063374 description "научни чланак" @default.
• Q102063374 description "научни чланак" @default.
• Q102063374 description "מאמר מדעי" @default.
• Q102063374 description "مقالة علمية نشرت في 14 نوفمبر 2020" @default.
• Q102063374 description "১৪ নভেম্বর ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q102063374 description "บทความทางวิทยาศาสตร์" @default.
• Q102063374 description "სამეცნიერო სტატია" @default.
• Q102063374 name "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 name "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 name "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 type Item @default.
• Q102063374 label "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 label "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 label "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 prefLabel "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 prefLabel "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 prefLabel "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.
• Q102063374 P1433 Q102063374-422A1575-175F-4EC4-89A5-9F268317FC9F @default.
• Q102063374 P1476 Q102063374-8CEADABF-7DF3-4BA9-9FDD-65C4039FE744 @default.
• Q102063374 P2093 Q102063374-11E073C0-BEB8-4822-BE1B-32148804CC65 @default.
• Q102063374 P2093 Q102063374-1BD64D8A-3F5E-4A9B-8E85-CA99A89DAD80 @default.
• Q102063374 P2093 Q102063374-23F848E0-4B2E-46E4-A3C4-E3CE01596CC9 @default.
• Q102063374 P2093 Q102063374-2DE72760-8AF1-40A9-9A3A-BD7C36C7BC87 @default.
• Q102063374 P2093 Q102063374-40A6A06A-C7A2-487F-BC50-85ADD8BBF19C @default.
• Q102063374 P2093 Q102063374-4FF3199E-C787-4A0B-A3F5-47F28F3EC7CE @default.
• Q102063374 P2093 Q102063374-525E76A6-D87C-41EA-B121-6DD8BBC80DC7 @default.
• Q102063374 P2093 Q102063374-6189796A-3548-4AE2-BCC0-A9D2647CADEA @default.
• Q102063374 P2093 Q102063374-65950A10-0CB6-4590-886D-9E41F3A70C84 @default.
• Q102063374 P2093 Q102063374-BB3DF345-D7DA-4C3A-AEE4-3BE1ACFABA75 @default.
• Q102063374 P2093 Q102063374-BE516607-3E83-4995-9989-F12E3B46E16F @default.
• Q102063374 P2093 Q102063374-DFAE6BEA-7D6D-473A-849E-E9EB37066C29 @default.
• Q102063374 P275 Q102063374-dfc7f835-e0f4-4429-9b24-624f2bb1a1f8 @default.
• Q102063374 P304 Q102063374-6D2D2E63-CB1F-460D-8209-9F0F08A1BBF6 @default.
• Q102063374 P31 Q102063374-E6860617-0715-4A59-8FE6-39F00830FD80 @default.
• Q102063374 P356 Q102063374-60C4B26B-D4CA-483E-B2FE-91D037EACEAC @default.
• Q102063374 P433 Q102063374-0378D9AA-9E04-4EB8-AC53-BD6BF8B39D63 @default.
• Q102063374 P478 Q102063374-FB5F0E4D-C724-48B7-8770-067D191DEBE4 @default.
• Q102063374 P50 Q102063374-9328E9EF-76A7-43E9-8A83-DFD193AFA0EE @default.
• Q102063374 P50 Q102063374-D3ACB34C-5393-4C2D-893F-2C35602D0176 @default.
• Q102063374 P577 Q102063374-E378B332-DCD5-4B3E-9A26-ACFD8F7BB641 @default.
• Q102063374 P6216 Q102063374-2b94c426-0014-40f9-8b15-9d6d7eb42076 @default.
• Q102063374 P698 Q102063374-97FDB2C7-FBE0-4508-A4A3-B986C8DD01DA @default.
• Q102063374 P921 Q102063374-3D0C3BFC-D722-4699-90B5-42D1BBB92F92 @default.
• Q102063374 P921 Q102063374-4DEC2446-4296-47FC-9C8D-41A910DA3D30 @default.
• Q102063374 P356 BMJOPEN-2020-039951 @default.
• Q102063374 P698 33191263 @default.
• Q102063374 P1433 Q17003470 @default.
• Q102063374 P1476 "Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial" @default.

• next